Product Highlight - ZAVICEFTA

• Broad spectrum coverage of aerobic gram-negative pathogens including:
     – Carbapenem-resistant Enterobacteriaceae (KPC and OXA-48),
     – P. aeruginosa (including many ceftazidime-resistant strains), and
     – ESBL-producing Enterobacteriaceae¹
• Indicated in adults, infants (aged 3 months and older), children, and adolescents for the treatment of:
     – Complicated intra-abdominal infection (cIAI)
     – Complicated urinary tract infection (cUTI), including pyelonephritis
     – Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)¹
• Also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with cIAI, cUTI, or HAP/VAP.¹
• Recommended by the Infectious Diseases Society of America (IDSA) guidance as a preferred treatment option for carbapenem-resistant Enterobacteriaceae (CRE) infections.²
• A safety and tolerability profile consistent with both cephalosporins and carbapenems.^3-6

References:
1. Zavicefta (Ceftazidime and Avibactam) Singapore Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=13526.
2. Tamma PD, et al. Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections. 2020. Available at: https://www.idsociety.org/practice-guideline/amr-guidance.
3. Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.
4. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.
5. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.
6. Torres A, et al. Lancet Infect Dis 2018;18:285–95. 

 

References on file.
For healthcare professionals only.

PP-ZVA-SGP-0290/24APR2023